Cephapirin (with Peanut Oil) Formulation

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier
   Trade name : Cephapirin (with Peanut Oil) Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against
   Use of the Substance/Mixture : Veterinary product

1.3 Details of the supplier of the safety data sheet
   Company : MSD
   Kilsheelan
   Clonmel Tipperary, IE
   Telephone : 353-51-601000
   E-mail address of person responsible for the SDS : EHSDATASTEWARD@msd.com

1.4 Emergency telephone number
   +1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture
   Classification (REGULATION (EC) No 1272/2008)
   Respiratory sensitisation, Category 1 H334: May cause allergy or asthma symptoms or breathing difficulties if inhaled.

2.2 Labelling (REGULATION (EC) No 1272/2008)
   Hazard pictograms :
   Signal word : Danger
   Hazard statements : H334 May cause allergy or asthma symptoms or breathing difficulties if inhaled.
   Precautionary statements : Response:
   P304 + P340 IF INHALED: Remove person to fresh air and keep comfortable for breathing.
   P342 + P311 If experiencing respiratory symptoms: Call a POISON CENTER/ doctor.
Hazardous components which must be listed on the label:
Cefapirin

Additional Labelling
The following percentage of the mixture consists of ingredient(s) with unknown hazards to the aquatic environment: 3.2 %

2.3 Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>EC-No. Index-No.</th>
<th>Classification</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cefapirin</td>
<td>21593-23-7 244-466-5</td>
<td>Resp. Sens. 1A; H334</td>
<td>&gt;= 1 - &lt; 10</td>
<td></td>
</tr>
</tbody>
</table>

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

General advice: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

Protection of first-aiders: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

If inhaled: If inhaled, remove to fresh air. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical attention.
In case of skin contact: Wash with water and soap as a precaution. Get medical attention if symptoms occur.

In case of eye contact: Flush eyes with water as a precaution. Get medical attention if irritation develops and persists.

If swallowed: If swallowed, DO NOT induce vomiting. Get medical attention if symptoms occur. Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed
Risks: May cause allergy or asthma symptoms or breathing difficulties if inhaled.

Excessive exposure may aggravate preexisting asthma and other respiratory disorders (e.g. emphysema, bronchitis, reactive airways dysfunction syndrome).

4.3 Indication of any immediate medical attention and special treatment needed
Treatment: Treat symptomatically and supportively.

SECTION 5: Firefighting measures

5.1 Extinguishing media
Suitable extinguishing media: Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
Dry chemical

Unsuitable extinguishing media: None known.

5.2 Special hazards arising from the substance or mixture
Specific hazards during firefighting: Exposure to combustion products may be a hazard to health.

Hazardous combustion products: Carbon oxides
Metal oxides

5.3 Advice for firefighters
Special protective equipment for firefighters: In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

Specific extinguishing methods: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions: Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions: Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g. by containment or oil barriers). Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up: Soak up with inert absorbent material. For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absorbent. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures: See Engineering measures under EXPOSURE CONTROLS/PERSOHAL PROTECTION section.

Local/Total ventilation: Use only with adequate ventilation.

Advice on safe handling: Avoid breathing mist or vapours. Do not swallow. Avoid contact with eyes. Avoid prolonged or repeated contact with skin. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment. Keep container tightly closed. Already sensitised individuals should consult their physician regarding working with respiratory irritants or sensitisers. Take care to prevent spills, waste and minimize release to the
Hygiene measures: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers: Keep in properly labelled containers. Keep tightly closed. Store in accordance with the particular national regulations.

Advice on common storage: Do not store with the following product types: Strong oxidizing agents

7.3 Specific end use(s)

Specific use(s): No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cefapirin</td>
<td>21593-23-7</td>
<td>TWA</td>
<td>0.4 mg/m³ (OEB 2)</td>
<td>Internal</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Further information: RSEN</td>
<td></td>
</tr>
</tbody>
</table>

8.2 Exposure controls

Engineering measures

Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Laboratory operations do not require special containment.

Personal protective equipment

Eye protection: Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Hand protection

Material: Chemical-resistant gloves

Skin and body protection: Work uniform or laboratory coat.
Cephapirin (with Peanut Oil) Formulation

Respiratory protection: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection. Equipment should conform to NS EN 14387

Filter type: Combined particulates and organic vapour type (A-P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Physical state: suspension
Colour: No data available
Odour: No data available
Odour Threshold: No data available
Melting point/freezing point: No data available
Initial boiling point and boiling range: No data available
Flammability (solid, gas): Not applicable
Flammability (liquids): No data available
Upper explosion limit / Upper flammability limit: No data available
Lower explosion limit / Lower flammability limit: No data available
Flash point: No data available
Auto-ignition temperature: No data available
Decomposition temperature Decomposition temperature: No data available
pH: No data available
Viscosity
Viscosity, kinematic: No data available
Solubility(ies)
Water solubility: No data available
Partition coefficient: n-octanol/water: Not applicable
Vapour pressure: No data available
Relative density: No data available
Density: No data available
Relative vapour density: No data available
Particle characteristics
Particle size : Not applicable

9.2 Other information
Explosives : Not explosive
Oxidizing properties : The substance or mixture is not classified as oxidizing.
Evaporation rate : No data available
Molecular weight : No data available

SECTION 10: Stability and reactivity

10.1 Reactivity
Not classified as a reactivity hazard.

10.2 Chemical stability
Stable under normal conditions.

10.3 Possibility of hazardous reactions
Hazardous reactions : Can react with strong oxidizing agents.

10.4 Conditions to avoid
Conditions to avoid : None known.

10.5 Incompatible materials
Materials to avoid : Oxidizing agents

10.6 Hazardous decomposition products
No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008
Information on likely routes of exposure : Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity
Not classified based on available information.

Components:
Cefapirin:
Acute oral toxicity : LD50 (Mouse): 26.000 mg/kg
Acute toxicity (other routes of administration) : LD50 (Mouse): > 7.600 mg/kg
Application Route: Intraperitoneal
LD50 (Rat): 7.800 mg/kg
Application Route: Intraperitoneal

Skin corrosion/irritation
Not classified based on available information.

Serious eye damage/eye irritation
Not classified based on available information.

Respiratory or skin sensitisation

Skin sensitisation
Not classified based on available information.

Respiratory sensitisation
May cause allergy or asthma symptoms or breathing difficulties if inhaled.

Components:

Cefapirin:
Assessment: Probability or evidence of high respiratory sensitisation rate in humans

Germ cell mutagenicity
Not classified based on available information.

Components:

Cefapirin:
Genotoxicity in vitro: Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Carcinogenicity
Not classified based on available information.

Reproductive toxicity
Not classified based on available information.

Components:

Cefapirin:
Effects on fertility: Test Type: Fertility/early embryonic development
Species: Rat
Application Route: Intraperitoneal injection
Fertility: LOAEL: > 500 mg/kg body weight
Result: No effects on fertility

Effects on foetal development: Test Type: Embryo-foetal development
Species: Rat
Application Route: Intraperitoneal injection
Developmental Toxicity: LOAEL: > 200 mg/kg body weight
STOT - single exposure
Not classified based on available information.

STOT - repeated exposure
Not classified based on available information.

Repeated dose toxicity

Components:

Cefapirin:
Species : Rat
LOAEL  : \( \geq 200 \text{ mg/kg} \)
Application Route : Intraperitoneal
Target Organs : Blood
Remarks : anemia

Species : Dog
LOAEL  : 20 mg/kg
Application Route : Oral
Exposure time : 4 Months
Target Organs : Gastrointestinal tract

Species : Dog
LOAEL  : 100 mg/kg
Application Route : Intramuscular
Exposure time : 10 Months
Target Organs : Blood, Gastrointestinal tract
Remarks : anemia

Aspiration toxicity
Not classified based on available information.

11.2 Information on other hazards

Endocrine disrupting properties

Product:
Assessment : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Experience with human exposure

Components:

Cefapirin:
Ingestion : Symptoms: Nausea, Vomiting, Abdominal pain, Diarrhoea, vaginitis, colitis, anorexia, Rash, anaphylaxis
Cephapirin (with Peanut Oil) Formulation

SECTION 12: Ecological information

12.1 Toxicity
No data available

12.2 Persistence and degradability
No data available

12.3 Bioaccumulative potential
No data available

12.4 Mobility in soil
No data available

12.5 Results of PBT and vPvB assessment

**Product:**
Assessment: This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

12.6 Other adverse effects

**Product:**
Endocrine disrupting potential: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

SECTION 13: Disposal considerations

13.1 Waste treatment methods

**Product:**
Dispose of in accordance with local regulations.
According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.

**Contaminated packaging:**
Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number or ID number
Not regulated as a dangerous good

14.2 UN proper shipping name
Not regulated as a dangerous good
Cephapirin (with Peanut Oil) Formulation

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, preparations and articles (Annex XVII) : Conditions of restriction for the following entries should be considered: Number on list 3

REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59). : Not applicable

REACH - List of substances subject to authorisation (Annex XIV) : Not applicable

Regulation (EC) No 1005/2009 on substances that deplete the ozone layer : Not applicable

Regulation (EU) 2019/1021 on persistent organic pollutants (recast) : Not applicable

Regulation (EC) No 649/2012 of the European Parliament and the Council concerning the export and import of dangerous chemicals : Not applicable


Other regulations:
Young people under the age of 18 are not allowed to use or be exposed to the product professionally. Young people above the age of 15 are, however, except from this rule if the product is a necessary part of their education.

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

15.2 Chemical safety assessment
A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information
Cephapirin (with Peanut Oil) Formulation

Other information:
Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Full text of H-Statements:
H334: May cause allergy or asthma symptoms or breathing difficulties if inhaled.

Full text of other abbreviations:
Resp. Sens.: Respiratory sensitisation

Further information:
Sources of key data used to compile the Safety Data Sheet:

Classification of the mixture:
Resp. Sens. 1 H334

Classification procedure:
Calculation method
The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.